Prostate cancer screening

JAMA - Journal of the American Medical Association

Volumn 314, Issue 8, 2015, Pages 825-826

  Eggener, Scott E ^a   Cifu, Adam S ^a   Nabhan, Chadi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; HEALTH CARE COST; HUMAN; METASTASIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION; SHORT SURVEY; ADULT; ADVERSE EFFECTS; AGE; AGED; BIOPSY; BLOOD; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS;

ADULT; AGE FACTORS; AGED; BIOPSY; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84940499484     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.8033     Document Type: Short Survey

References (10)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Efstathiou JA, Chen MH, CatalonaWJ, et al. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006;68(2):342-347.
3. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
4. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419-426.
5. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 2011;107(6):882-891.
6. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the ERSPC at 13 years of follow-up. Lancet. 2014; 384(9959):2027-2035.
7. Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the ERSPC. Eur Urol. 2009;56(4):584-591.
8. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, andOvarian Cancer Screening Trial. J Natl Cancer Inst. 2012;104(2):125-132.
9. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830-1834.
10. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181.